Related Experiment Videos
[Persistent pulmonary hypertension in newborn infants]
C M Pedersen1, T G Hansen, S W Henneberg
1Odense Universitetshospital, anaestesi- og intensivafdeling V.
Ugeskrift for Laeger
|July 7, 1997
Summary
Persistent pulmonary hypertension of the newborn (PPHN) is reviewed, focusing on pathophysiology and treatments like inhaled nitric oxide. Further randomized trials are needed to confirm the routine use of nitric oxide for PPHN.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Respiratory Physiology
Context:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition requiring specialized management.
- Current therapeutic strategies include mechanical ventilation, pharmacological vasodilation, and extracorporeal membrane oxygenation.
- Understanding PPHN pathophysiology is key to developing effective treatments.
Purpose:
- To review the current literature on persistent pulmonary hypertension of the newborn.
- To discuss the pathophysiology, diagnostic criteria, and treatment options for PPHN.
- To evaluate the role of inhaled nitric oxide in PPHN management.
Summary:
- This review covers PPHN, detailing its pathophysiology, diagnosis, and treatments such as mechanical ventilation and vasodilation.
- Inhaled nitric oxide is highlighted as a selective pulmonary vasodilator that can improve ventilation/perfusion mismatching.
- The article emphasizes the need for more randomized trial data with long-term follow-up before recommending routine inhaled nitric oxide therapy for PPHN.
Impact:
- Provides a comprehensive overview of PPHN for clinicians and researchers.
- Highlights the potential benefits and limitations of inhaled nitric oxide therapy.
- Guides future research directions for optimizing PPHN treatment strategies.